SEATTLE, WA / ACCESSWIRE / August 27, 2019 / MHHC Enterprises, Inc. (fka McCusker Holdings Corp) (OTC PINK:MHHC), a leading provider of help desk, warranty services and complementary enterprise businesses, announced effective with FINRA on August 26th, 2019 our new company name is MHHC Enterprises, Inc. MHHC Enterprises, Inc. is the parent company to MHHC Warranty and Services Inc., and MHHC Reinsurances Inc., as well as other developing enterprises.

“Our organization has undergone significant transformation over the past 24-months”, says Frank Hawley, CEO and Board President of MHHC Enterprises Inc. “MHHC transformation includes the elimination of all debt, divesting or the elimination of all non-profitable entities, quality infrastructure to provide excellent customer service, timely processing claims, and complete quality repairs for customers. Most important MHHC transformation has staged the organization for steady growth in both the consumer and manufacturer warranty business, and consistent revenue growth and value for our shareholders.”

MHHC second quarter earnings grew at 16% over the same quarter of 2018, and early 3rd quarter 2019 revenues show consistent growth as well. Additionally, MHHC prides itself that it is currently debt free, and has zero toxic loans.

In 2019, MHHC has signed two new contracts, one of which is a 3-year agreement valued at over $2.4 million that will eventually expand our retail footprint to over 1,000 retail outlets that will sell our extended service contracts across the United States. The second contract provides for MHHC expanded warranty service with a manufacturer of audio equipment that will deliver significant long-term revenue value to the organization.

MHHC’s new contractual arrangements with business partners will help our organization in managing customer service, processing claims, and facilitating the engagement of new retail locations that will help further grow revenues.

By the close of 2019, MHHC will be operating in all 50-states. Currently, we are licensed in over 35 states. MHHC Warranty and Services Inc. is a highly regulated enterprise, requiring quality underwriting and licensing. Our primary focus for the past several months has been to achieve A-rated plus underwriting and expending resources to meet regulatory requirements. Both goals have been achieved and are constantly being maintained through the hard work of Company management.

“MHHC remains confident that our reorganization and streamlining of all the components of the old and outdated way of doing business under the previous leadership is now complete. Our best practices have implemented an integrated and lean dynamic structure that will produce quality and sustainable results for shareholders. Our staff efforts and relationships with the MHHC business partners are producing excellent results and will continue to do so moving forward.” said CEO Frank Hawley.

Please submit any Investor Relations questions or comments to operationsmgr@mhhcco.com.

Safe Harbor and Forward-Looking Statements

This news release contains statements that involve expectations, plans or intentions (such as those relating to future expansion or financial results) and other factors discussed from time to time in the Company’s OTC Markets filings. These statements are forward-looking and are subject to risks and uncertainties, so actual results may vary materially. You can identify these forward-looking statements by words such as “may,” “should,” “expect,” “anticipate,” “believe,” “estimate,” “intend,” “plan” and other similar expressions. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of certain factors not within the control of the company. The company cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date made. The company disclaims any obligation subsequently to revise any forward-looking statements to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events.

CONTACT:

MHHC Enterprises, Inc.
operationsmgr@mhhcco.com

SOURCE: MHHC Enterprises, Inc.

ReleaseID: 557577

NEW YORK, NY / ACCESSWIRE / August 27, 2019 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.

Diebold Nixdorf, Incorporated (NYSE:DBD)

If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/diebold-nixdorf-incorporated-loss-submission-form?prid=3203&wire=1
Lead Plaintiff Deadline: September 3, 2019
Class Period: February 14, 2017 to August 1, 2018

Allegations against DBD include that: (1) as a result of the Wincor acquisition and related integration, the Company was less focused on its core business; (2) the Company expected certain customers would not renew their service contracts (i.e. contract runoff); (3) the Company was not adequately prepared to staff service technicians; (4) as a result of the expected contract runoff, the Company would suffer a shortage of adequately trained service technicians; (5) as a result, the Company would suffer margin pressure in its services segment; (6) as a result of the foregoing, the Company would lose market share; and (7) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

CannTrust Holdings Inc. (NYSE:CTST)

If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/canntrust-holdings-inc-loss-submission-form?prid=3203&wire=1
Lead Plaintiff Deadline: September 9, 2019
Class Period: November 14, 2018 to July 12, 2019

According to filed complaints, CannTrust Holdings Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) the Company was growing cannabis in its Pelham greenhouse while applications for regulatory approval were still pending; (2) the Company’s Pelham greenhouse did not comply with certain regulations; (3) as a result, the Company was reasonably likely to face an inventory hold by Health Canada until the Pelham facility becomes compliant with applicable regulations; (4) as a result, the Company’s customers would face shortages and would likely seek product from CannTrust’s competitors; and (5) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially false and/or misleading and/or lacked a reasonable basis.

Curaleaf Holdings, Inc. (OTCQX:CURLF)

If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/curaleaf-holdings-inc-loss-submission-form?prid=3203&wire=1
Lead Plaintiff Deadline: October 4, 2019
Class Period: November 21, 2018 to July 22, 2019

Allegations against CURLF include that: (1) Curaleaf, on its website and social media pages, marketed its CBD products to be used as drugs and dietary supplements, contrary to law; (2) Curaleaf also sold unapproved animal drugs on its website; (3) such conduct would result in a warning letter from the U.S. Food and Drug Administration; and (4) as a result, Defendants’ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

To learn more contact Vincent Wong, Esq. either via email vw@wongesq.com or by telephone at 212.425.1140.

Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: vw@wongesq.com

SOURCE: The Law Offices of Vincent Wong

ReleaseID: 557580

NEW YORK, NY / ACCESSWIRE / August 27, 2019 / Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Cardinal Health, Inc. (“Cardinal Health” or the “Company”) (NYSE:CAH) of the September 30, 2019 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

If you invested in Cardinal Health stock or options between March 2, 2015 and May 2, 2018 and would like to discuss your legal rights, click here: www.faruqilaw.com/CAH. There is no cost or obligation to you.

You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to rgonnello@faruqilaw.com.

CONTACT:

FARUQI & FARUQI, LLP
685 Third Avenue, 26th Floor
New York, NY 10017
Attn: Richard Gonnello, Esq.
rgonnello@faruqilaw.com
Telephone: (877) 247-4292 or (212) 983-9330

The lawsuit has been filed in the U.S. District Court for the Southern District of Ohio on behalf of all those who purchased Cardinal Health common stock between March 2, 2015 and May 2, 2018 (the “Class Period”). The case, Louisiana Sheriffs Pension & Relief Fund v. Cardinal Health, Inc., No. 19-cv-03347 was filed on August 1, 2019, and has been assigned to Judge Edmund A. Sargus.

The lawsuit focuses on whether the Company and its executives violated federal securities laws by misleading investors by stating that Cordis Corp. (“Cordis”), a manufacturer of medical devices that Cardinal purchased from Johnson & Johnson in March of 2015, would benefit from Cardinal’s advanced inventory management and supply chain information technology solutions.

On August 2, 2017, Cardinal reported weak earnings for its fourth quarter and fiscal year 2017 and lowered its earnings guidance for fiscal year 2018 due in part to “higher-than-planned write-offs for excess inventory” at Cordis.

On this news, the Company’s stock price fell from $77.33 per share on August 1, 2017 to $70.99 per share on August 2, 2017, a $6.34 or 8.20% drop.

Then, on May 3, 2018, Cardinal announced disappointing results for its third quarter fiscal year 2018 and cut its fiscal year 2018 earnings guidance. The Company explained that the “biggest variable driving these results” was the “disappointing performance” of the Cordis business. Contrary to the Company’s prior statements that it had visibility into Cordis’s inventory and that the Company properly reserved for obsolete inventory, the Company revealed that after launching a new global supply chain IT platform over the last quarter at Cordis, it discovered millions of dollars of unsellable and expired heart stents and catheters stationed overseas that had to be written off.

On this news, the Company’s stock price fell from $64.65 per share on May 2, 2018 to $50.80 per share on May 3, 2018, a $13.85 or 21.42% drop.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.

Faruqi & Faruqi, LLP also encourages anyone with information regarding Cardinal Health’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

SOURCE: Faruqi & Faruqi, LLP

ReleaseID: 557508

NEW YORK, NY / ACCESSWIRE / August 27, 2019 / Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Carbonite, Inc. (“Carbonite” or the “Company”)(NASDAQ:CARB) of the September 30, 2019 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

If you invested in Carbonite stock or options between February 7, 2019 and July 25, 2019 and would like to discuss your legal rights, click here: www.faruqilaw.com/CARB. There is no cost or obligation to you.

You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to rgonnello@faruqilaw.com.

CONTACT:

FARUQI & FARUQI, LLP
685 Third Avenue, 26th Floor
New York, NY 10017
Attn: Richard Gonnello, Esq.
rgonnello@faruqilaw.com
Telephone: (877) 247-4292 or (212) 983-9330

The lawsuit has been filed in the U.S. District Court for the District of Massachusetts on behalf of all those who purchased Carbonite common stock between February 7, 2019 and July 25, 2019 (the “Class Period”). The case, Luna v. Carbonite, Inc., No. 19-cv-11662 was filed on August 1, 2019, and has been assigned to Judge Leo T. Sorokin.

The lawsuit focuses on whether the Company and its executives violated federal securities laws by failing to disclose that: (1) Carbonite’s Server Backup VM Edition was of poor quality and technologically flawed; (2) Carbonite was receiving poor reviews and complaints from customers about the Server Backup VM Edition; and (3) the poor quality and technological flaws of the Server Backup VM Editio

On July 25, 2019, Carbonite announced that it was withdrawing the Server Backup VM Edition from the marketplace and consequently lowering its financial projections for fiscal 2019 and 2020. The same day, Carbonite’s Chief Executive Officer announced he was leaving the Company.n were acting as a “disruptive” factor throughout the Carbonite salesforce and keeping that sales organization from closing opportunistically on several larger deals during fiscal 2019.

On this news, Carbonite’s share price fell from $23.90 per share on July 25, 2019 to a closing price of $18.01 on July 26, 2019: a $5.89 or a 24.64% drop.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.

Faruqi & Faruqi, LLP also encourages anyone with information regarding Carbonite’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

SOURCE: Faruqi & Faruqi, LLP

ReleaseID: 557505

PARADISE VALLEY, AZ / ACCESSWIRE / August 27, 2019 / Business owner, founder and real estate investor, Jay Bansal is a force to be reckoned with. An entrepreneur at heart, he has ushered the corporate world into the 21st century.

Initiating projects like iMed Transport, a company that simplifies hospital logistics and patient care, and playing a key role in several real estate projects, former lawyer Jay Bansal and his wife Rajani Bansal are used to taking business risks.

Jay A. Bansal‘s real estate endeavors have completely changed the status quo. Convenience stores, gas stations, hotel and apartment projects have molded the razor-sharp work ethic he is known for. Today, he is a respected thought leader in the market and shares many of his business habits with budding investors across the globe.

Study the Ins and Outs of the Market

Jay Ankur Bansal is a big believer in rigorous research that leaves no stone unturned. His mantra? “Business professionals have to know their target market’s interest and attraction to properly analyze the market.”

Study the marketplace microscopically, stay abreast of current trends, measure consumer behaviors, mortgage rates, and forecasted real estate patterns. Attorney Jay Bansal pushes investors to make a holistic plan for the future so that no opportunity is unspoken for.

Know Your Niche

Focus is everything, without it, an investor is like a fish out of water. Jay A. Bansal encourages that entrepreneurs block out the noise and focus on developing a depth of knowledge in one niche.

All successful real estate investors have spent a lot of time excelling in one niche initially. This spells long-term success. Ask yourself; Should I invest in luxury condominiums? Or do distressed properties attract my interest? Using this same in-depth approach, real estate investors can then proceed to conquer other segments of the market.

Referrals Are Your Friend

The major slice of a real investor’s pie is, you guessed it, referrals. Jay Ankur Bansal advocates that it’s very important for investors to build human connections with partners, associates, clients, renters – anyone who comes their way.

When you pay attention and proactively address complaints – people take notice. You become an investor that has represented themselves in a positive light, and left a lasting mark on the minds of potential clients.

Don’t Undermine Risks

With sizeable reward, there is a sizeable risk. Lawyer Jay Bansal reminds investors to remain prudent and take into consideration the risks that the future presents. Advertisements in the market tend to gloss over potential red flags, it’s important to go out of your way to learn about the legal implications that are interwoven into deals of this nature.

The Road Ahead

So what does the future hold for lawyer Jay A. Bansal? For now, he continues to oversee his thriving real estate investment deals, setting his sights on Phoenix’s apartment scene.

Jay Bansal and his wife of 25 years, Rajani Bansal, have created a corporate and philanthropic empire and look forward to bringing attention to worthy causes that they can proudly stand behind.

CONTACT:
Caroline Hunter
Web Presence, LLC
+1 7865519491

SOURCE: Web Presence, LLC

ReleaseID: 557575

NEW YORK, NY / ACCESSWIRE / August 27, 2019 / Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Abiomed, Inc. (“Abiomed” or the “Company”)(NASDAQ:ABMD) of the October 7, 2019 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

If you invested in Abiomed stock or options between January 31, 2019 and July 31, 2019 and would like to discuss your legal rights, click here: www.faruqilaw.com/ABMD. There is no cost or obligation to you.

You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to rgonnello@faruqilaw.com.

CONTACT:

FARUQI & FARUQI, LLP
685 Third Avenue, 26th Floor
New York, NY 10017
Attn: Richard Gonnello, Esq.
rgonnello@faruqilaw.com
Telephone: (877) 247-4292 or (212) 983-9330

The lawsuit has been filed in the U.S. District Court for the Southern District of New York on behalf of all those who purchased Abiomed securities between January 31, 2019 and July 31, 2019 (the “Class Period”). The case, Villare v. Abiomed, Inc., No. 19-cv-07319 was filed on August 6, 2019.

The lawsuit focuses on whether the Company and its executives violated federal securities laws by failing to disclose that (1) Abiomed’s revenue growth was in decline; (2) the Company did not have a sufficient plan in place to stem its declining revenue growth; (3) the Company was unlikely to restore its revenue growth over the next several fiscal quarters; (4) consequently, Abiomed was reasonably likely to revise its full-year 2020 guidance in a way that would fall short of the Company’s prior projections and market expectations; and (5) as a result, the Company’s public statements were materially false and misleading at all relevant times.

On August 1, 2019, the Company issued a press release announcing its financial and operating results for the first quarter of fiscal year 2020. Among other results, the press release disclosed Abiomed’s third consecutive quarter of slowing revenue growth, reporting “first-quarter fiscal 2020 revenue of $207.7 million, an increase of 15.4% compared to revenue of $180.0 million for the same period of fiscal 2019”. This represented a significant decrease in revenue growth from 2Q 2019. Commenting on the Company’s surprising financial result disappointment, the Company’s Chairman, President, and CEO, Michael R. Minogue, revealed that the Company’s “new training programs, organizational changes in distribution, and [] external initiatives… will require time to drive more growth in the future.”

The Company also slashed its previously issued full-year 2020 guidance from total revenues in the range of $900-945 million to total revenues in the range of $885-925 million, which fell roughly $22 million short of market expectations.

On this news, Abiomed’s share price fell from $278.56 per share on July 31, 2019 to a closing price of $204.87 on August 1, 2019: a $73.69 or a 26.54% drop.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.

Faruqi & Faruqi, LLP also encourages anyone with information regarding Abiomed’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

SOURCE: Faruqi & Faruqi, LLP

ReleaseID: 557504